NCT05199272 - A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Biotech Hunter

Enrollment

141

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions

Solid TumorClear Cell Renal Cell CarcinomaEpithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CarcinomaNeuroendocrine TumorsMSI-H CancerCancer With A High Tumor Mutational BurdenExtensive-stage Small-cell Lung Cancer

Interventions

DRUG

23ME-00610

23ME-00610 given by IV infusion

Trial Locations (13)

11040

Cohen Children's Medical Center, New Hyde Park

11042

R.J.Zuckerberg Cancer Center, Lake Success

22031

Virginia Cancer Specialists, Fairfax

30322

Emory University, Atlanta

37232

Vanderbilt University, Nashville

48201

Karmanos Cancer Institute, Detroit

77030

MD Anderson Cancer Center, Houston

78229

START Center for Cancer Care, San Antonio

94304

Stanford Cancer Institute, Palo Alto

97239

Oregon Health & Science University, Portland

K1H 8L6

Ottawa Hospital Cancer Centre, Ottawa

M5G 2M9

Princess Margaret Cancer Centre, Toronto

M5G1X8

The Hospital for Sick Children, Toronto